Introduction {#S1}
============

The loss of skeletal muscle mass with aging is a well-known phenomenon ([@B37]). Lean muscle mass decreases substantially after the age of 60 ([@B90]). Severe, aging-associated loss of muscle mass and strength, also termed sarcopenia ([@B118]) and dynapenia ([@B146]), respectively, have profound consequences that extend beyond simple loss of mobility ([@B151]). Specific diagnostic criteria for sarcopenia continues to evolve ([@B28]; [@B132]), but it manifests with increased insulin resistance, loss of bone density, and an increase in falls ([@B42]; [@B113]). As such, these patients are at an increased risk of all-cause mortality, incident and mobility disabilities, and loss of independence ([@B3]). From a public health perspective, the economic burden of caring for sarcopenic patients is tremendous and accounts for nearly \$28.5 billion per year in expenditures, after adjusting for inflation ([@B61]).

Many recent studies suggest that regimented physical activity, including resistance training, can be beneficial in maintaining muscle strength and function in elderly individuals ([@B99]; [@B84]; [@B89]; [@B117]; [@B156]). However, although physical training is beneficial at any age, the anabolic response to exercise decreases substantially with aging ([@B149]; [@B108]; [@B75]). This review explores the mechanisms of cellular and molecular adaptations of skeletal muscle to exercise, with a focus on the aging-associated changes that cause hinderance of its anabolic response to exercise. We further evaluate the efficacy of supplements commonly used with physical training to optimize the exercise benefit on skeletal muscle, with the ultimate goal of preventing sarcopenia and associated adverse events.

Skeletal Muscle and Aging {#S2}
=========================

Aging is associated with changes in multiple biological processes and impacts nearly every facet of tissue homeostasis ([@B83]). Changes specific to skeletal muscle include diminished fiber number and cross-sectional area ([@B79]), a decline in fast-twitch muscle-fibers ([@B78]), and increased fat infiltration ([@B87]). These structural changes are responsible for the loss of strength that accompanies muscle aging ([@B138]; [@B36]). A complex network of signaling factors are precisely regulated to maintain myogenesis and muscle mass. Protein metabolism is regulated by Akt and mammalian target of rapamycin (mTOR) signaling pathways, which are, in turn, activated by various anabolic stimuli to bring about hypertrophic response in skeletal muscle. The induction of the insulin-like growth factor (IGF) pathway, upstream of Akt/mTOR prevents muscle atrophy ([@B155]), highlighting its importance in the maintenance of muscle mass. The circulating levels of IGF-1 and IGF-1 binding proteins are decreased in aging, with a corollary reduction in mTOR activation in sarcopenic individuals ([@B100]; [@B76]; [@B31]; [@B125]).

The maintenance of muscle mass may be further limited by diminished nutritional stimuli due to poor nutritional intake ([@B17]). A lack of nutrients, including essential amino acids (EAAs), is further paired with improper post-prandial nutrient handling in the elderly ([@B147]). These changes contribute to an inability to increase muscle protein synthesis in response to exercise or nutritional availability and results in muscle atrophy with aging ([@B150]). The inability to properly utilize nutrition is synonymous with anabolic resistance, in which skeletal muscle in old age cannot gain mass despite appropriate cues. Two major factors contributing to this phenomenon in elderly subjects are poor nutrition and a reduction in regimented physical activity ([@B131]; [@B150]).

Muscle hypertrophy can also be negatively regulated by catabolic signals, most prominent of which are the transforming growth factor (TGF)-β superfamily and related cytokines. Myostatin and TGF-β both limit muscle hypertrophy by regulating the expression of genes involved in differentiation and proliferation in muscle stem cells ([@B73]; [@B154]), increasing protein degradation ([@B122]), and inhibiting mTOR activation by anabolic stimuli in mature myofibers ([@B141]). While their role in sarcopenia remains unclear, some studies have shown that an age-related increase in TGF-β signaling from myofibers occurs in parallel with a decline in Notch signaling in satellite cells ([@B27]; [@B23]), thus resulting in a reduced regenerative capacity of aged muscle. Myostatin was found to be increased in type II muscle fibers ([@B127]), suggesting that myostatin may play a role in selective type II fiber atrophy as seen in old age.

Androgenic depravation may be a factor contributing to sarcopenia in old males ([@B64]; [@B65]; [@B85]). Testosterone promotes skeletal muscle hypertrophy directly by increasing protein synthesis ([@B43]) and muscle stem cell division ([@B111]), and indirectly by increasing IGF-1 expression via ERK and mTOR signaling ([@B123]). The exact role of testosterone in sarcopenia remains to be established; however, a study reported a significant association between serum-free testosterone and muscle mass in well-nourished, elderly men ([@B7]). A corollary study demonstrated that lower circulating testosterone was associated with decreased maximal performance capacity in elderly men ([@B52]).

Chronic inflammation, as occurs with aging, has been shown to have detrimental effects on muscle physiology. In particular, the NF-κB pathway may be causative in limiting skeletal muscle repair following injury and hastening atrophy ([@B80]). NF-κB is highly expressed in elderly people with muscle wasting ([@B16]) and its level correlates with decreased anabolic response ([@B29]). In multiple preclinical models, NF-κB limited myoblast differentiation and regeneration following injury ([@B97]). Taken together, the evidence suggests that pharmacological inhibition of chronically activated NF-κB may limit aging-associated muscle loss. Indeed, non-steroidal anti-inflammatory drugs (NSAID)s promote muscle regeneration following injury, although its benefit in limiting sarcopenia remains to be elucidated ([@B137]; [@B97]).

In addition to alterations in the systemic milieu, intrinsic changes within myofibers and muscle stem cells with aging also affects the ability of skeletal muscle to respond to anabolic stimuli. Hyperphosphorylation of mTORC1, which impairs its activation ([@B63]), is found in aged muscle of human ([@B88]). Therefore, defective mTOR signaling likely underlies the resistance of skeletal muscle to anabolic stimuli ([@B51]), insulin resistance ([@B114]), and impaired protein/glucose homeostasis in aged skeletal muscle ([@B104]). Mitochondrial dysfunction has also been associated with sarcopenia ([@B26]) and mitochondrial DNA damage has been shown to cause muscle wasting ([@B1]). While there are no pharmacotherapeutics that are efficacious in attenuating skeletal muscle loss in aging, resistance training may limit some of these pathologic aging associated changes in skeletal muscle by augmenting mTOR activity ([@B130]).

Effect of Resistance Exercise Training on Skeletal Muscle {#S3}
=========================================================

Physical activity, especially resistance training, is unequivocally beneficial for elderly patients with regards to enhancing muscle mass and strength ([@B44]; [@B33]; [@B106]; [@B39]). A recent review found that when progressive resistance training (PRT) is performed 2--3 times a week at a high intensity, it results in improved physical function and strength ([@B81]). The frequency and duration of resistance exercise in elderly are recommended at 2--4 times per week on alternating days and lasting 30--60 min each; 1--3 sets of 8--15 reps at 80% of one-rep maximum strength, with a monthly progressive adjustment ([@B2]; [@B74]). In skeletal muscle, functional overload induces hypertrophy resulting in increased muscle mass and fiber size in a dose-dependent manner ([@B48]). Previous studies have demonstrated that resistance exercise or muscle contraction increases overall muscle protein turnover in favor of protein synthesis through the activation of the mTOR pathway ([@B12]). In addition to its direct anabolic effect, exercise has been shown to increase the circulating levels of IGF-1 ([@B15]) and androgens ([@B53]), while decreasing myostatin levels ([@B59]). Furthermore, physical activity promotes restoration of insulin sensitivity, mitochondrial biogenesis, and reduces inflammation ([@B94]; [@B19]).

Attenuated Exercise Benefit in the Elderly on Muscle Mass and Strength {#S4}
======================================================================

Despite the consensus that regimented physical training is beneficial for the maintenance of strength and function, numerous studies suggest that the effects of exercise on skeletal muscle physiology decreases with aging. Anabolic resistance describes the inability of the body to add muscle mass despite physical activity ([@B71]; [@B115]; [@B46]). In older patients, the increase in lean muscle mass following resistance exercise training is substantially less than younger subjects ([@B102]). As such, the gain in strength following regimented exercise programs are substantially less in the elderly ([@B149]; [@B67]; [@B14]). Diminished induction of muscle regeneration following exercise further dampens the overall hypertrophic response in the elderly ([@B96]; [@B8]; [@B133]). In addition, elderly patients suffer from impaired muscle activation secondary to aging-associated changes in motor unit density and morphology ([@B20]; [@B112]; [@B57]). Resistance exercise training improves innervation and thus muscle strength in elderly even without fiber hypertrophy ([@B91]). Despite exercise, however, the numbers of motor units may still decline with aging ([@B110]; [@B109]), limiting the functional improvement attainable from exercise. Understanding the limitations of resistance training and potential mechanisms underlying this phenomenon is critical for improving exercise benefit in the elderly population.

Optimizing Skeletal Muscle Response to Exercise in Aging {#S5}
========================================================

Nutritional Supplementation {#S5.SS1}
---------------------------

The acute anabolic responses to feeding and exercise were found to be dampened in old subjects compared to their young counterparts, thus limiting their recovery, and muscle growth ([@B29]; [@B41]). It has been hypothesized that the blunted increase in protein synthesis following acute muscle loading may influence the smaller gains in lean tissue following resistance exercise training in older adults ([@B41]). As such, supplementation of high-quality protein may improve anabolic response to a single bout of exercise ([@B38]; [@B35]; [@B103]). Whole protein supplements such as whey and casein, both milk-derivatives, are popularly ingested with the intention to increase muscle mass. Casein, when used as a pre-sleep protein supplement, has been shown to increase myofibrillar protein synthesis rates overnight in older adults ([@B68]). When combined with a bout of resistance exercise in the evening, rates of protein synthesis were even higher ([@B60]). While fiber hypertrophy was seen with pre-sleep protein ingestion during a resistance training regimen in young men ([@B129]), outcomes in older individuals require further investigation ([@B60]).

Specific amino acid supplements are also available, in the forms of EAAs, branched-chain amino acids (BCAAs), and leucine. Leucine-rich EAA supplementation enhanced muscle strength following exercise, although the study included elderly women only ([@B66]). It is important to note, however, that prolonged protein supplementation with whey or casein, in the setting of a training program, does not appear to improve the exercise response in elderly patients ([@B49]; [@B70]; [@B144]). β-hydroxy-β-methylbutyrate (HMB), a metabolite of leucine which directly activates mTOR, has also been investigated and increased lean muscle mass and strength in sarcopenic individuals ([@B98]). In total, protein and amino acids are a promising exercise supplement for the elderly. Current recommendations for daily protein intake in most older individuals are 1.2--1.5 grams protein/kilogram body weight ([@B40]). Interventional trials are required to identify the appropriate composition of proteins and/or amino acids, as well as the timing of delivery.

Separately, creatine is essential for muscle ATP production and has been commonly ingested to enhance anabolic response to exercise. Multiple studies have presented some evidence that creatine treatment, in combination with resistance training, enhances gains in muscle mass and strength following exercise beyond what is attainable with resistance exercise alone ([@B22]). The benefit of creatine therapy alone without resistance training remains unclear; some have suggested that creatine ingestion improves lean muscle mass in the elderly ([@B50]), whereas others have observed no benefit in muscle mass or strength with creatine administration ([@B82]; [@B4]; [@B24]). However, in elderly subjects, supplementing resistance training with creatine increased lean muscle mass and strength when compared to placebo ([@B21]; [@B32]; [@B25]). In addition to its known role in ATP production, numerous studies suggest that creatine's positive effect on aging muscle may work through several mechanisms, including by inducing proteins downstream of the mTOR pathway ([@B121]), decreasing protein degradation ([@B101]), and functioning as an antioxidant ([@B124]). Importantly, creatine therapy appears to have a low risk profile with minimal adverse effects ([@B69]), making it an attractive supplement.

Other recently proposed nutritional supplements to counter sarcopenia and dynapenia include vitamin D and omega-3 polyunsaturated fatty acids. Vitamin D is diminished by up to 4 fold in older adults ([@B86]). Low vitamin D levels have been linked to muscle atrophy ([@B145]). Several studies found that vitamin D3 supplementation in the elderly results in increased muscle strength ([@B92]) as well as reduction in falls and fractures when combined with calcium ([@B107]). However, others have reported no improvement in functional capacity with vitamin D supplementation ([@B142]; [@B77]; [@B126]). Omega-3, commonly found in fatty fish and seafood, may also limit sarcopenia progression and improve protein synthesis in response to anabolic stimuli ([@B128]). In addition, multiple studies show that omega-3 augments the effects of resistance training and further increases muscle mass and strength in older adults ([@B116]; [@B30]). Further interventional studies will be required to better define the efficacy and dosage for these compounds, but both are potentially efficacious supplements.

Multi-ingredient protein (MIP)-based supplements may prove to be more efficacious in improving muscle mass and strength gains with exercise as compared to single nutritional supplements alone. In a clinical trial, a MIP supplement consisting of whey protein, creatine, calcium, vitamin D, eicosapentaenoic acid, and docosahexanoic acid improved both lean muscle mass and strength in elderly patients, during exercise, as compared to placebo ([@B9]; [@B95]). However, within a metanalysis, there was no benefit in muscle strength and mass, as compared to protein supplementation alone, in response to exercise ([@B95]). This highlights that future research must focus on defining specific combinations and dosages.

NSAID Therapy {#S5.SS2}
-------------

Chronic, age-related inflammation in skeletal muscle may play a role in aging-associated muscle loss ([@B5]). As mentioned previously, NF-κB, a master transcriptional regulator of inflammation, becomes upregulated in skeletal muscle with aging ([@B54]). This has led to investigations of whether NF-κB inhibition using commercially available NSAIDs can improve the maintenance of muscle mass ([@B153]). Inhibition of NF-κB directly improves muscle regeneration after injury in aged muscle ([@B97]) and limits muscle atrophy by decreasing MuRF signaling ([@B18]). The efficacy of NF-κB inhibition, using commercially available NSAIDs, on the maintenance of muscle mass and strength in response to exercise has been explored in many clinical studies in elderly patients. A 3-month bout of resistance exercise in elderly patients with knee osteoarthritis, NSAIDs therapy resulted in a mild improvement in muscle strength, however, without hypertrophy ([@B105]). Other studies found that NSAID treatment augmented training-induced improvement in strength with associated muscle hypertrophy and limited muscle catabolism ([@B139], [@B140]). Others have instead shown that NSAID supplementation does not improve skeletal muscle strength or function during physical training ([@B34]). In addition, it should be noted that NSAID therapy is not without its risks in the elderly population. Chronic NSAID use can result in risk of renal failure, cardiovascular events, and gastrointestinal ulceration ([@B152]). As such, the use of NSAIDs during exercise remains a controversial, but potential treatment to augment response to exercise in the aging population. Improved specificity and identifying the correct dosage are, however, requisite to further promotion of this therapy.

Testosterone Therapy {#S5.SS3}
--------------------

Testosterone has emerged as another potential supplement to exercise for the elderly population. Multiple studies have demonstrated that testosterone levels decrease with age ([@B93]; [@B148]). Testosterone administration to elderly patients increases both muscle mass and maximal voluntary strength in a dose-dependent fashion, possibly by the induction of myogenic gene expression ([@B11]). Despite this assertion, the additional benefits of physiological testosterone replacement in elderly patients remains unclear. A prospective study demonstrated increased upper body strength following testosterone treatment of elderly patients with low to normal serum testosterone, but this treatment did not offer any benefit beyond resistance exercise alone ([@B58]). Others have similarly reported no synergistic or additional benefits of testosterone treatment in PRT ([@B134]). Of note, this is in direct contrast to the benefits of supra-physiological testosterone supplementation with regards to muscle strength and mass in young men, in whom combined treatment with testosterone and exercise was more efficacious than treatment with testosterone or exercise alone ([@B10]). Therefore, it is necessary to consider adjustment of the duration and dosage of testosterone supplementation in exercise regimens for the elderly before conclusion about its efficacy can be drawn. Additionally, like NSAID therapy, testosterone supplementation does not come without potential adverse events, and therefore the clinical efficacy of testosterone for sarcopenia treatment should be carefully evaluated ([@B6]).

Growth Hormone/Insulin-Like Growth Factor Supplementation {#S5.SS4}
---------------------------------------------------------

The growth hormone (GH) axis is another area that has received attention as a potential supplement for exercise therapy for the elderly. GH is made in the pituitary gland and promotes IGF-1 (insulin growth factor) expression in skeletal muscle ([@B62]; [@B143]). IGF-1, in turn, stimulates the Akt/mTOR pathway which, as discussed before, promotes muscle anabolism and protein synthesis in response to exercise ([@B13]). In elderly patients, GH treatment increases lean body mass and decreases fat-to-muscle ratio from baseline, although it is unclear as to whether this was attributable to increased skeletal muscle mass ([@B120], [@B119]). However, multiple studies have shown that healthy elderly patients do not see any additional benefit in strength or muscle hypertrophy with GH supplementation as compared to exercise alone, even at 6-month follow-up ([@B136], [@B135]; [@B56]; [@B72]), despite confirmation of increased levels of circulating IGF-1. Interestingly, IGF-1 administration in isolation does not increase lean muscle mass. Its effects in combination with exercise, however, have not been independently tested ([@B47]). Separately, losartan, an angiotensin II type I receptor blocker which potentiates IGF-1 activity, failed to improve the anabolic response to physical resistance training ([@B55]). Despite the integral role of the GH/IGF axis on muscle development or hypertrophy, it does not appear to have a therapeutic benefit in physical training in healthy individuals.

Conclusion {#S6}
==========

Aging is a complex and heterogenous process. It is, however, uniformly associated with loss of skeletal muscle mass, strength, and function. Resistance exercise in older patients unequivocally results in substantial benefits exemplified by muscle fiber hypertrophy, increased strength, extended independent living, and reduced fall risk ([@B45]). Many efforts have focused on improving this response further with nutritional supplements, anti-inflammatory drugs, and anabolic agents. While numerous studies have reported synergistic benefits of combining a supplement with exercise, many others suggest marginal benefits versus exercise alone, especially in elderly individuals. Future studies should utilize a standard resistance training regimen, guided by previously published position statements ([@B2]), with resistance exercise three times weekly at 30 min per bout at 60--80% resistance. Moreover, supplements must be individualized to patients. Elderly patients with low levels of IGF-1 or testosterone may benefit from those specific supplements, where as other elderly patients may not. New studies may focus on MIP therapies combining supplements which have demonstrated significant benefit with regards to muscle mass and strength during exercise, such as combining EAAs, Creatinine, Vitamin D, and omega-3 fatty acids. Heterogeneity in the patient population, physical training intensity, and duration of interventions make it difficult to draw generalizable conclusions, but understanding the mechanisms of anabolic resistance and augmenting response to exercise is paramount to maintaining muscle strength and function in aging.
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